JP6387219B2 - Skin external preparation composition containing tangeretin and EGCG - Google Patents
Skin external preparation composition containing tangeretin and EGCG Download PDFInfo
- Publication number
- JP6387219B2 JP6387219B2 JP2013015044A JP2013015044A JP6387219B2 JP 6387219 B2 JP6387219 B2 JP 6387219B2 JP 2013015044 A JP2013015044 A JP 2013015044A JP 2013015044 A JP2013015044 A JP 2013015044A JP 6387219 B2 JP6387219 B2 JP 6387219B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- extract
- egcg
- green tea
- tangeretin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 51
- 238000002360 preparation method Methods 0.000 title claims description 13
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 title description 56
- IECRXMSGDFIOEY-UHFFFAOYSA-N Tangeretin Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 IECRXMSGDFIOEY-UHFFFAOYSA-N 0.000 title description 28
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 title description 25
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title description 25
- 239000000284 extract Substances 0.000 claims description 28
- 229940094952 green tea extract Drugs 0.000 claims description 24
- 235000020688 green tea extract Nutrition 0.000 claims description 24
- 241000207199 Citrus Species 0.000 claims description 16
- 241001672694 Citrus reticulata Species 0.000 claims description 16
- 235000020971 citrus fruits Nutrition 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 5
- 102000011782 Keratins Human genes 0.000 claims description 5
- 108010076876 Keratins Proteins 0.000 claims description 5
- 229960005323 phenoxyethanol Drugs 0.000 claims description 5
- 244000269722 Thea sinensis Species 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 3
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 3
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 3
- 235000013616 tea Nutrition 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 48
- 239000002537 cosmetic Substances 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 25
- 239000000126 substance Substances 0.000 description 24
- 230000002087 whitening effect Effects 0.000 description 23
- 239000002552 dosage form Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 239000006210 lotion Substances 0.000 description 13
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 239000006071 cream Substances 0.000 description 12
- -1 pack Substances 0.000 description 11
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 206010040880 Skin irritation Diseases 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 239000000049 pigment Substances 0.000 description 9
- 230000036556 skin irritation Effects 0.000 description 9
- 231100000475 skin irritation Toxicity 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 4
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 4
- 229960004705 kojic acid Drugs 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000289 Polyquaternium Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- YFOURACIUPVFFK-UHFFFAOYSA-N 2-[hydroxy-(6-oxo-3,7-dihydropurin-2-yl)amino]acetic acid Chemical compound O=C1NC(N(CC(O)=O)O)=NC2=C1NC=N2 YFOURACIUPVFFK-UHFFFAOYSA-N 0.000 description 1
- NALUDDWNDBCDQS-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound C(C)C(O)(C(O)CO)CCCCCC.C(C)C(O)(C(O)CO)CCCCCC NALUDDWNDBCDQS-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229930182496 polymethoxyflavone Natural products 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- E—FIXED CONSTRUCTIONS
- E03—WATER SUPPLY; SEWERAGE
- E03C—DOMESTIC PLUMBING INSTALLATIONS FOR FRESH WATER OR WASTE WATER; SINKS
- E03C1/00—Domestic plumbing installations for fresh water or waste water; Sinks
- E03C1/02—Plumbing installations for fresh water
- E03C1/04—Water-basin installations specially adapted to wash-basins or baths
- E03C1/0412—Constructional or functional features of the faucet handle
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K11/00—Multiple-way valves, e.g. mixing valves; Pipe fittings incorporating such valves
- F16K11/02—Multiple-way valves, e.g. mixing valves; Pipe fittings incorporating such valves with all movable sealing faces moving as one unit
- F16K11/06—Multiple-way valves, e.g. mixing valves; Pipe fittings incorporating such valves with all movable sealing faces moving as one unit comprising only sliding valves, i.e. sliding closure elements
- F16K11/065—Multiple-way valves, e.g. mixing valves; Pipe fittings incorporating such valves with all movable sealing faces moving as one unit comprising only sliding valves, i.e. sliding closure elements with linearly sliding closure members
- F16K11/07—Multiple-way valves, e.g. mixing valves; Pipe fittings incorporating such valves with all movable sealing faces moving as one unit comprising only sliding valves, i.e. sliding closure elements with linearly sliding closure members with cylindrical slides
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K31/00—Actuating devices; Operating means; Releasing devices
- F16K31/44—Mechanical actuating means
- F16K31/60—Handles
- F16K31/602—Pivoting levers, e.g. single-sided
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S303/00—Fluid-pressure and analogous brake systems
- Y10S303/10—Valve block integrating pump, valves, solenoid, accumulator
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hydrology & Water Resources (AREA)
- Public Health (AREA)
- Water Supply & Treatment (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、タンゲレチン及びEGCGを含有することにより、美白効果を有する皮膚外用剤組成物に関する。 The present invention relates to a skin external preparation composition having a whitening effect by containing tangeretin and EGCG.
人の肌色を決めるには様々な要因が関与するが、その中でも、メラニン色素を作るメラノサイト(melanocyte)の活動性、血管の分布、皮膚の厚さ、及びカロチノイドとビリルビンなど人体内外の色素の含有の有無などが重要な要因となる。 Various factors are involved in determining human skin color. Among them, the activity of melanocytes that produce melanin pigment, distribution of blood vessels, skin thickness, and inclusion of pigments inside and outside the human body such as carotenoids and bilirubin The presence or absence of this is an important factor.
その中で、特に最も重要な要因は、人体内のメラノサイトでチロシナーゼなどの様々な酵素が作用して生成されるメラニンという黒色の色素である。このメラニン色素の形成には、遺伝的な要因、ホルモンの分泌、ストレスなどに関連する生理的要因と、紫外線照射などのような環境的要因などが影響を及ぼす。 Among them, the most important factor is a black pigment called melanin that is produced by the action of various enzymes such as tyrosinase in melanocytes in the human body. The formation of this melanin pigment is influenced by genetic factors, hormone secretion, physiological factors related to stress, and environmental factors such as ultraviolet irradiation.
身体皮膚のメラニン細胞から生成されるメラニン色素は、黒い色素とタンパク質の複合体の形態を有するフェノール系高分子物質であって、太陽から照射される紫外線を遮断して、真皮以下の皮膚器官を保護するとともに、皮膚生体内に生じたフリー・ラジカルなどを捉えてくれるなど、皮膚内のタンパク質と遺伝子を保護する有用な役割を担当する。 Melanin pigment produced from melanocytes in the body skin is a phenolic polymer substance in the form of a complex of black pigment and protein, blocking the ultraviolet rays irradiated from the sun, and the skin organs below the dermis In addition to protecting and capturing free radicals generated in the skin, it is responsible for protecting the proteins and genes in the skin.
このように、皮膚内、外部のストレスのような刺激によって生じたメラニンは、ストレスが消えても、皮膚角質化を通じて外部に排出されるまでは、なくならない安定した物質である。しかしながら、メラニンが必要以上に多くできると、シミ、ソバカス及びほくろなどのような過色素沈着症を誘発して、美容上に良くない結果をもたらすことになる。 As described above, melanin generated by stimulation such as external stress in the skin is a stable substance that does not disappear until the stress disappears until it is discharged to the outside through skin keratinization. However, more melanin than necessary can cause hyperpigmentation such as stains, buckwheat and moles, resulting in poor cosmetic results.
今日、東洋の女性たちは、白くてきれいな白玉肌を好み、これを美しさの重要な基準としているため、過色素沈着に対する治療及び美容上の問題を解決しようとする要求が増えることになった。 Today, Oriental women prefer white and clean white skin and make this an important standard of beauty, which has led to an increasing demand for treatment and cosmetic problems for hyperpigmentation. .
このような要求に応じて、従来から、アスコルビン酸、コウジ酸、アルブチン、ハイドロキノン、グルタチオン若しくはこれらの誘導体、又はチロシナーゼ阻害活性を有する物質を、化粧料や医薬品に配合して使用してきたが、これらの不充分な美白効果、皮膚に対する安全性の問題、化粧料に配合する際に現れる剤形及び安定性の問題などにより、その使用が制限されている。したがって、皮膚に、より安全ながらも優れた美白効果を有する組成物の開発が切実に要請されている実情である。 In response to such demands, ascorbic acid, kojic acid, arbutin, hydroquinone, glutathione or derivatives thereof, or substances having tyrosinase inhibitory activity have been used in cosmetics and pharmaceuticals. Its use is limited by insufficient whitening effect, safety problems on the skin, dosage forms appearing when blended into cosmetics and stability problems. Accordingly, there is an urgent need for the development of a composition that has an excellent whitening effect while being safer on the skin.
本発明の発明者は、多様な実験を繰り返して、ミカンの皮抽出物に含まれたタンゲレチン(tangeretin)と緑茶抽出物に含まれたEGCG(Epigallocatechin gallate)を共に使用することにより、皮膚に対して安全ながらも優れた美白効果を提供することができることを確認し、本発明を完成するに至った。 The inventor of the present invention repeats various experiments and uses both tangeretin contained in the mandarin peel extract and EGCG (Epigallocatechin gallate) contained in the green tea extract to the skin. It has been confirmed that an excellent whitening effect can be provided while being safe, and the present invention has been completed.
したがって、本発明の目的は、タンゲレチン及びEGCGを有効成分として含有する皮膚外用剤組成物を提供することにある。 Accordingly, an object of the present invention is to provide a skin external preparation composition containing tangeretin and EGCG as active ingredients.
前記目的を達成するために、本発明は、タンゲレチン及びEGCGを有効成分として共に含有する美白用の皮膚外用剤の組成物を提供する。 In order to achieve the above object, the present invention provides a skin whitening composition for whitening containing both tangeretin and EGCG as active ingredients.
本発明の組成物は、タンゲレチンにEGCGをさらに含有することにより、優れた皮膚美白効果を示し、これを通じて化粧品又は医薬分野で多様に活用可能である。 The composition of the present invention shows an excellent skin whitening effect by further containing EGCG in tangeretin, and can be used in various ways in the cosmetics or pharmaceutical fields.
本発明の皮膚外用剤組成物は、タンゲレチン及びEGCGを有効成分として共に含有する。また、本発明は、ミカンの皮抽出物に含まれたタンゲレチン及び緑茶抽出物に含まれたEGCGを使用することにより、皮膚に刺激を与えず、安全ながら皮膚美白効果を有する皮膚外用剤組成物を提供する。 The skin external preparation composition of the present invention contains both tangeretin and EGCG as active ingredients. In addition, the present invention provides a skin external preparation composition that has a skin whitening effect safely without causing irritation to the skin by using tangeretin contained in a citrus peel extract and EGCG contained in a green tea extract. I will provide a.
以下、本発明を詳細に説明する。
本発明で使用するタンゲレチンは、ミカンの皮抽出物に含まれたものが好ましい。タンゲレチンは、シトラスフラボノイド系であり、O−ポリメトキシレートフラボン(O−polymethoxylated flavones)の構造を有し、本発明で使用するタンゲレチンは、シトラスフラボノイド系であり、O−ポリメトキシレートフラボン(O−polymethoxylated flavones)の構造を有する。フラボン(flavones)類の中で、ポリメトキシフラボン(polymethoxyflavone)類は、他の野菜および果物には殆どなく、ミカン類の特徴的な成分であって、フラボノイド(flavonoid)に5個のメトキシが置換されている物質である。タンゲレチンは、下記の化学式1で表現される。
Hereinafter, the present invention will be described in detail.
The tangeretin used in the present invention is preferably contained in a citrus peel extract. The tangeretin is a citrus flavonoid type and has a structure of O-polymethoxylate flavones, and the tangeretin used in the present invention is a citrus flavonoid type, and O-polymethoxylate flavone (O- (polymethylated flavones). Among flavones, polymethoxyflavones are rarely found in other vegetables and fruits, and are characteristic components of mandarin oranges. Five methoxys are substituted for flavonoids. It is a substance that has been. Tangeretin is represented by the following chemical formula 1.
本発明の一実施例において、前記ミカンの皮抽出物は、組成物の総質量に対して0.001〜40質量%に含まれてもよい。ミカンの皮抽出物が0.001質量%未満に含まれると、前記成分による効能、効果が微弱であり、40質量%を超えると、皮膚刺激による安全性の問題又は剤形上の安定度の問題があるためである。 In one embodiment of the present invention, the citrus peel extract may be included in an amount of 0.001 to 40% by mass based on the total mass of the composition. When the citrus peel extract is contained in an amount of less than 0.001% by mass, the effects and effects of the above components are weak, and when it exceeds 40% by mass, there is a problem of safety due to skin irritation or the stability of the dosage form. This is because there is a problem.
本発明で使用するEGCGは、緑茶抽出物に含まれたものが好ましい。EGCGは、タンニン又はポリフェノールの構成成分であり、強力な美白効果を有し、下記の化学式2の構造で表現される。 The EGCG used in the present invention is preferably contained in a green tea extract. EGCG is a constituent of tannin or polyphenol, has a strong whitening effect, and is represented by the structure of the following chemical formula 2.
また、本発明の一実施例において、前記緑茶抽出物は、組成物総質量に対して0.001〜40質量%に含まれてもよい。緑茶抽出物が0.001質量%未満に含まれると、前記成分による効能、効果が微弱であり、40質量%を超えると、皮膚刺激のような安全性問題又は剤形上の安定性問題があるためである。 Moreover, in one Example of this invention, the said green tea extract may be contained in 0.001-40 mass% with respect to the composition total mass. If the green tea extract is contained in less than 0.001% by mass, the effects and effects of the above ingredients are weak, and if it exceeds 40% by mass, there are safety problems such as skin irritation or stability problems in the dosage form. Because there is.
本発明で使用されたタンゲレチンを含有するミカンの皮抽出物及びEGCGを含有する緑茶抽出物を製造する方法は、特別に制限されるものではなく、本発明の一実施例において前記抽出物は、原料を有機溶媒に沈漬して抽出した後、濾過、減圧及び濃縮して得られた濃縮物を使用することができる。又は、前記濃縮物を再び乾燥して製造した浸剤、前剤、丁幾及び流動エキスを使用することができる。前記沈漬物は、ミカンの皮又は緑茶溶媒を用いて、冷浸、パーコーレーション(percolation)、温浸などの任意の方法を通じて沈漬し、有効成分を含有する沈漬物を得ることができる。前記有機溶媒は、C1〜C4の無水又は含水アルコール、アセトン、エチルアセテート、クロロホルム、グリセリン、プロピレングリコール及びブチレングリコールの中から選択された一つ以上のものであってもよいが、これに制限されるものではない。 The method for producing a mandarin peel extract containing tangeretin and a green tea extract containing EGCG used in the present invention is not particularly limited, and in one embodiment of the present invention, the extract comprises: After the raw material is immersed in an organic solvent and extracted, a concentrate obtained by filtration, reduced pressure and concentration can be used. Alternatively, it is possible to use a soaking agent, a pre-preparation, a clove and a fluid extract produced by drying the concentrate again. The submerged product can be submerged using citrus peel or green tea solvent through any method such as cooling, percolation, digestion, etc. to obtain a submerged product containing an active ingredient. The organic solvent may be one or more selected from C 1 to C 4 anhydrous or hydrous alcohols, acetone, ethyl acetate, chloroform, glycerin, propylene glycol, and butylene glycol. It is not limited.
一方、本発明の一実施例において、前記組成物は、皮膚紅斑防止用又は肌色改善用であってもよい。また、本発明の一実施例において、前記組成物は、皮膚老化防止、皮膚弾力増大、皮膚シワ改善、血色改善、毛穴収縮、皮膚刺激緩和、恒常性向上、スリミング、アトピー、抗菌、アレルギー、弾力、にきび、再生、皮脂、老廃物、角質改善効果、皮膚収斂及び整頓の効果を有するだけでなく、肥満、糖尿改善用であってもよいが、これに限定されるものではない。 Meanwhile, in one embodiment of the present invention, the composition may be for preventing skin erythema or improving skin color. In one embodiment of the present invention, the composition may be used to prevent skin aging, increase skin elasticity, improve skin wrinkles, improve blood color, shrink pores, alleviate skin irritation, improve homeostasis, slimming, atopy, antibacterial, allergy, elasticity In addition to acne, regeneration, sebum, waste products, keratin improving effect, skin convergence, and organizing effect, it may be used for improving obesity and diabetes, but is not limited thereto.
本発明による皮膚外用剤組成物は、一般的に皮膚外用に使用する組成物の全般を包括する概念であり、例えば、化粧料組成物、薬学組成物である。 The skin external preparation composition according to the present invention is a concept that generally encompasses all the compositions used for external skin use, such as a cosmetic composition and a pharmaceutical composition.
化粧料組成物としては、例えば、基礎化粧料、メーキャップ化粧料、毛髪用の化粧料、ボディー用の化粧料などがあり、その剤形は特別に制限されず、目的とするところにより適切に選択することができる。 Cosmetic compositions include, for example, basic cosmetics, makeup cosmetics, hair cosmetics, body cosmetics, etc. The dosage form is not particularly limited and is appropriately selected depending on the intended purpose. can do.
例えば、前記化粧料組成物は、溶液、懸濁液、乳濁液、ペースト、ゲル、クリーム、ローション、パウダー、石鹸、界面活性剤含有クレンジング、オイル、粉末ファンデーション、乳濁液ファンデーション、ワックスファンデーション及びスプレーなどに剤形化されてもよいが、これに限定されるものではない。より詳しくは、柔軟化粧水、栄養化粧水、ローション、ボディーローション、栄養クリーム、マッサージクリーム、モイスチャークリーム、ハンドクリーム、エッセンス、アイクリーム、クレンジングクリーム、クレンジングフォーム、クレンジングウォーター、パック、ゲル、パッチ、水中油(O/W)型、油中水(W/O)型などの基礎化粧料、リップスティック、メーキャップベース又はファンデーションなどの色調化粧料、シャンプー、リンス、ボディークレンザー、歯磨き又は口腔清浄剤などの洗浄料、ヘアトニック、ゲル又はムースなどの整髪剤、養毛剤又は毛染め剤などの毛髪用の化粧料組成物に剤形化されてもよい。 For example, the cosmetic composition is a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, It may be formulated into a spray or the like, but is not limited thereto. In more detail, soft lotion, nourishing lotion, lotion, body lotion, nourishing cream, massage cream, moisture cream, hand cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, gel, patch, underwater Basic cosmetics such as oil (O / W) type, water-in-oil (W / O) type, color cosmetics such as lipstick, makeup base or foundation, shampoo, rinse, body cleanser, toothpaste or oral cleanser It may be formulated into a cosmetic composition for hair such as a hair styling agent such as a cleaning agent, hair tonic, gel or mousse, a hair nourishing agent or a hair dyeing agent.
前記化粧料組成物は、化粧品学的に許容可能な媒質又は基剤を含有する。これは局所適用に適したすべての剤形であって、例えば、溶液、ゲル、固体又は練り無水生成物、水相に油相を分散させて得たエマルジョン、懸濁液、マイクロエマルジョン、マイクロカプセル、微細顆粒球若しくはイオン型(リポソーム)及び/又は非イオン型の小胞分散剤の形態であり、若しくは、クリーム、スキン、ローション、パウダー、軟膏、スプレー又はコンシールスティックの形態で提供される。これらの組成物は、当該分野の通常的な方法により製造される。 The cosmetic composition contains a cosmetically acceptable medium or base. This is all dosage forms suitable for topical application, eg solutions, gels, solids or kneaded anhydrous products, emulsions obtained by dispersing the oil phase in the aqueous phase, suspensions, microemulsions, microcapsules In the form of fine granulocytes or ionic (liposomes) and / or non-ionic vesicle dispersions, or in the form of creams, skins, lotions, powders, ointments, sprays or conceal sticks. These compositions are prepared by conventional methods in the art.
本発明において、剤形が溶液又は乳濁液である場合には、担体成分として、溶媒、溶解化剤又は乳濁化剤が利用され、例えば、水、エタノール、イソプロパノール、炭酸エチル、酢酸エチル、ベンジルアルコール、安息香酸ベンジル、プロピレン・グリコール、1,3−ブチルグリコールオイル、グリセロール脂肪族エステル、ポリエチレン・グリコール又はソルビタン脂肪酸エステルがある。 In the present invention, when the dosage form is a solution or an emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component. For example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, There are benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid ester.
本発明において、剤形が懸濁液である場合には、担体成分として、水、エタノール若しくはプロピレングリコールのような液状の希釈剤、エトキシ化イソステアリルアルコール、ポリオキシエチレンソルビトールエステル、若しくはポリオキシエチレンソルビタンエステルのような懸濁剤、微少結晶性セルロース、アルミニウムメタ水酸化物、ベントナイト、寒天又はトラカントなどが利用される。 In the present invention, when the dosage form is a suspension, the carrier component is water, a liquid diluent such as ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, or polyoxyethylene. Suspending agents such as sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant are used.
本発明において、剤形がペースト、クリーム又はゲルである場合には、担体成分として、動物性の油、植物性の油、ワックス、パラピン、澱粉、トラカント、セルロース誘導体、ポリエチレングリコール、シリコン、ベントナイト、シリカ、タルク又は酸化亜鉛などが利用される。 In the present invention, when the dosage form is a paste, cream or gel, the carrier component is animal oil, vegetable oil, wax, parapine, starch, tracant, cellulose derivative, polyethylene glycol, silicon, bentonite, Silica, talc or zinc oxide is used.
本発明において、剤形がパウダー又はスプレーである場合には、担体成分として、ラクトース、タルク、シリカ、水酸化アルミニウム、ケイ酸カルシウム又はポリアミドパウダーが利用されてもよく、特に、剤形がスプレーである場合には、さらにクロロフルオロハイドロカーボン、プロパン、ブタン又はジメチルエーテルのような推進体を含んでもよい。 In the present invention, when the dosage form is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, the dosage form is a spray. In some cases, it may further include a propellant such as chlorofluorohydrocarbon, propane, butane or dimethyl ether.
本発明において、剤形が界面活性剤を含有するクレンジングである場合には、担体成分として、脂肪族アルコール硫酸塩、脂肪族アルコールエーテル硫酸塩、スルホコハク酸モノエステール、イセチオン酸、イミダゾリニウム誘導体、メチルタウレイト(methyltaurate)、サルコシネイト(sarcosinate)、脂肪酸アミドエーテル硫酸塩、アルキルアミドベタイン、脂肪族アルコール、脂肪酸グリセリド、脂肪酸ジエタノールアミド、植物性油、ラノリン誘導体又はエトキシ化グリセロール脂肪酸エステルなどが利用される。 In the present invention, when the dosage form is cleansing containing a surfactant, as a carrier component, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoesteral, isethionic acid, imidazolinium derivatives, Methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamide betaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester are used. .
本発明の一実施例において、前記化粧料組成物にさらに増粘剤を含有することができる。本発明の化粧料組成物に含まれる増粘剤は、メチルセルロース、カルボキシメチルセルロース、カルボキシメチルヒドロキシグアニン、ヒドロキシメチルセルロース、ヒドロキシエチルセルロース、カルボキシビニルポリマー、ポリクオタニウム、セテアリルアルコール、ステアリン酸、カラギナンなどを使用してもよい。好ましくは、カルボキシメチルセルロース、カルボキシビニルポリマー、ポリクオタニウムの中で1種以上を使用してもよく、最も好ましくは、カルボキシビニルポリマーを使用してもよい。 In one embodiment of the present invention, the cosmetic composition may further contain a thickener. As the thickener contained in the cosmetic composition of the present invention, methylcellulose, carboxymethylcellulose, carboxymethylhydroxyguanine, hydroxymethylcellulose, hydroxyethylcellulose, carboxyvinyl polymer, polyquaternium, cetearyl alcohol, stearic acid, carrageenan and the like are used. Also good. Preferably, one or more of carboxymethylcellulose, carboxyvinyl polymer, and polyquaternium may be used, and most preferably carboxyvinyl polymer may be used.
本発明の一実施例において、前記化粧料組成物は、必要に応じて適切な各種の基剤と添加剤を含有してもよく、これら成分の種類と量は、発明者によって容易に選ばれることができる。必要に応じて許容可能な添加剤を含有してもよく、例えば、当業界に通常の防腐剤、色素、添加剤などの成分をさらに含んでもよい。より詳しくは、防腐剤は、フェノキシエタノール(Phenoxyethanol)又は1,2−ヘキサンジオール(1,2−Hexanediol)等であってもよく、色素は、人工香料などであってもよい。 In one embodiment of the present invention, the cosmetic composition may contain various appropriate bases and additives as required, and the types and amounts of these components are easily selected by the inventor. be able to. If necessary, it may contain an acceptable additive. For example, it may further contain components such as preservatives, dyes, additives and the like which are usual in the art. More specifically, the preservative may be phenoxyethanol or 1,2-hexanediol, and the pigment may be an artificial fragrance.
そして、本発明の一実施例において、化粧料組成物は、水溶性ビタミン、油溶性ビタミン、高分子ペプチド、高分子多糖、スフィンゴ脂質及び海草エキスからなる群より選択された組成物を含んでもよい。それ以外に添加可能な配合成分としては、油脂成分、保湿剤、エモリアント剤、界面活性剤、有機又は無機顔料、有機粉体、紫外線吸収剤、防腐剤、殺菌剤、酸化防止剤、植物抽出物、pH調整剤、アルコール、色素、香料、血行促進剤、冷感剤、制汗剤、精製水などが挙げられる。 In one embodiment of the present invention, the cosmetic composition may include a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids, and seaweed extracts. . Other ingredients that can be added include oil and fat ingredients, moisturizers, emollients, surfactants, organic or inorganic pigments, organic powders, UV absorbers, preservatives, bactericides, antioxidants, plant extracts , PH adjusters, alcohols, pigments, fragrances, blood circulation promoters, cooling sensates, antiperspirants, purified water, and the like.
また、それ以外に添加可能な配合成分は、これに限定されるものではなく、また、前記のいずれの成分も、本発明の目的及び効果を損しない範囲内で配合することができる。 Moreover, the compounding component which can be added other than that is not limited to this, Moreover, all the said components can be mix | blended in the range which does not impair the objective and effect of this invention.
本発明の一実施例において、薬学組成物は、タンゲレチンを含有するミカンの皮抽出物及びEGCGを含有する緑茶抽出物を共に有効成分とし、常用の無機又は有機の担体を加えて、固体、半固体又は液状の形態で、非経口投与剤に製剤化することができる。前記非経口投与のための製剤としては、点滴剤、軟膏、ローション、ゲル、クリーム、パッチ、スプレー、懸濁剤及び油剤からなる群より選択された経皮投与型剤形であってもよいが、これに制限されるものではない。 In one embodiment of the present invention, the pharmaceutical composition comprises a tangerine peel extract containing tangeretin and a green tea extract containing EGCG as active ingredients, and a conventional inorganic or organic carrier is added to form a solid, semi-solid, It can be formulated into a parenteral administration agent in a solid or liquid form. The preparation for parenteral administration may be a transdermal dosage form selected from the group consisting of drops, ointments, lotions, gels, creams, patches, sprays, suspensions and oils. However, it is not limited to this.
各剤形による皮膚外用剤組成物において、上記した本発明の組成物以外の他の成分を、その他の皮膚外用剤の剤形又は使用の目的などによって、当業者が困難なく適宜選定して配合することができ、この場合、他の原料と同時に適用すると、相乗効果が起こることがある。 In the external preparation composition for skin according to each dosage form, other components other than the above-described composition of the present invention are appropriately selected and blended without difficulty by those skilled in the art according to the dosage form of other external preparation for skin or the purpose of use. In this case, a synergistic effect may occur when applied simultaneously with other ingredients.
また、本発明による組成物が薬学組成物として使用される場合、防腐剤、安定化剤、水化剤若しくは油化促進剤、浸透圧調節のための塩若しくは緩衝剤などの薬学的補助剤、又はその他の治療的に有用な物質をさらに含有することができ、通常の方法により多様な経口又は非経口投与の形態で剤形化することができる。 In addition, when the composition according to the present invention is used as a pharmaceutical composition, a pharmaceutical adjuvant such as a preservative, a stabilizer, a hydrating agent or an oiling accelerator, a salt or a buffer for adjusting osmotic pressure, Alternatively, it can further contain other therapeutically useful substances and can be formulated into various oral or parenteral dosage forms by conventional methods.
有効成分の実際の投与量は、症状の重症度、選択された投与経路、対象の年齢、性別、体重及び健康状態などの様々な関連因子によって決定すべきものとして理解しなければならない。 The actual dosage of the active ingredient should be understood as to be determined by various relevant factors such as the severity of the symptoms, the chosen route of administration, the age, sex, weight and health status of the subject.
一般的に有効成分の投与量は、約0.001mg/kg/日〜2000mg/kg/日の範囲である。さらに好ましい投与量は、0.5mg/kg/日〜2.5mg/kg/日である。 In general, the dosage of active ingredient ranges from about 0.001 mg / kg / day to 2000 mg / kg / day. A more preferable dose is 0.5 mg / kg / day to 2.5 mg / kg / day.
以下、試験例及び剤形例を挙げて、本発明の構成及び効果をより詳細に説明する。しかしながら、これらの試験例及び剤形例は、本発明に関する理解を助けるために例示の目的で提供されたもので、本発明の範疇及び範囲が下記の例によって制限されるものではない。 Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to test examples and dosage form examples. However, these test examples and dosage form examples are provided for illustrative purposes to assist in understanding the present invention, and the scope and scope of the present invention are not limited by the following examples.
[参考例1]タンゲレチンを含有するミカンの皮抽出物の製造
ミカンの皮を精製水で洗浄した後、乾燥の過程を経る。水気が除去されたミカンの皮を粉砕して40〜48時間、室温で冷浸抽出法を通じて有効成分を抽出する。抽出された内容物を250μm meshで1次濾過した後、遠心分離過程を通じて上層液を取る。その内容物をさらに3μm、1μm、0.5μm meshの濾過紙で順に濾過する。1,3−ブチレングリコール(Butylene glycol)10%、フェノキシエタノール(phenoxyethanol)0.5%、エチルヘキシルグリセリン(Ethylhexylglycerin)0.05%を追加し、さらに0.2〜0.3μmの濾過紙で濾過してミカンの皮抽出物を得る。
[Reference Example 1] Production of mandarin peel extract containing tangeretin The mandarin peel is washed with purified water and then dried. The citrus peel from which moisture has been removed is crushed and the active ingredients are extracted through a cold extraction method at room temperature for 40 to 48 hours. The extracted contents are first filtered with a 250 μm mesh, and then the upper layer liquid is taken through a centrifugation process. The contents are further filtered sequentially with 3 μm, 1 μm, and 0.5 μm mesh filter paper. Add 1,3-butylene glycol (Butylene glycol) 10%, phenoxyethanol 0.5%, ethylhexylglycerol (Ethylhexylglycerin) 0.05%, and filter with 0.2-0.3 μm filter paper. A mandarin peel extract is obtained.
[参考例2]EGCGを含有する緑茶抽出物の製造
茶葉を精製水で洗浄した後、乾燥の過程を経る。水気が除去された茶葉を粉砕して40〜48時間、室温で冷浸抽出法を通じて有効成分を抽出する。抽出された内容物を250μm meshで1次濾過した後、遠心分離過程を通じて上層液を取る。その内容物をさらに3μm、1μm、0.5μm meshの濾過紙で順に濾過する。1,3−ブチレン・グリコール10%、フェノキシエタノール0.5%、エチルヘキシルグリセリン0.05%を追加し、さらに0.2〜0.3μm濾過紙で濾過して緑茶抽出物を得る。
[Reference Example 2] Production of Green Tea Extract Containing EGCG After washing tea leaves with purified water, it undergoes a drying process. The tea leaves from which moisture has been removed are crushed and the active ingredients are extracted through a cold extraction method at room temperature for 40 to 48 hours. The extracted contents are first filtered with a 250 μm mesh, and then the upper layer liquid is taken through a centrifugation process. The contents are further filtered sequentially with 3 μm, 1 μm, and 0.5 μm mesh filter paper. Add 1,3-butylene glycol 10%, phenoxyethanol 0.5%, ethylhexylglycerin 0.05%, and further filter through 0.2-0.3 μm filter paper to obtain a green tea extract.
[試験例1]メラニン生成抑制効果
人間メラノマ細胞のHM3KO細胞(Y.Funasaka,Department of dermatology,Kobe university school of medicine,5−1 Kusunoki−cho 7−chrome,Chuo−ku,Kobe 650,Japan)をウシ胎児血清が10%入ったMEM(Minimum Essential Medium)に入れて、37℃、5%のCO2条件下で培養する。このように培養した細胞を、細胞数が各フラスコ当たり3×105になるように75フラスコに敷いて、一夜の間、細胞が器壁につくことを待ち、細胞がよくついたことを確認した後、培地を下記の表1の各試験物質が10ppm入っている新しい培地に取り替える。このとき、対照群は添加されない培地を使用し、ミカンの皮抽出物及び緑茶抽出物を共に使用したものを実施例1、美白効果を示すものと知られたコウジ酸を比較例1、ミカンの皮抽出物を比較例2、緑茶抽出物を比較例3とする。2〜3日ごとに一回ずつ試料が入っている新しい培地に取り替えながら、細胞がフラスコに満ちるまで培養する。細胞が成長し終えた後、集めて、対照群と実施例1、比較例1〜3の細胞の色をそれぞれ比較した。また、培養液を除去してPBSで洗浄した後、1N水酸化ナトリウムで溶かして500nmで吸光度を測定した後、下記の数学式1によりメラニン生成抑制率を計算し、その結果を下記の表1に示した。
[Test Example 1] Inhibitory effect on melanogenesis HM3KO cells of human melanoma cells (Y. Funasaka, Department of dermatology, KOBE university school of medicine, 501 Kusunoki-cho 7-cho 7 It is placed in MEM (Minimum Essential Medium) containing 10% fetal bovine serum and cultured under conditions of 37 ° C. and 5% CO 2 . Place the cells cultured in this way in 75 flasks so that the number of cells is 3 x 10 5 per flask, and wait for the cells to attach to the wall for one night. After that, the medium is replaced with a fresh medium containing 10 ppm of each test substance shown in Table 1 below. At this time, the control group used a medium not added, and used both citrus peel extract and green tea extract as Example 1, Kojic acid known to show a whitening effect as Comparative Example 1, citrus The skin extract is referred to as Comparative Example 2, and the green tea extract is referred to as Comparative Example 3. Incubate until the cells fill the flask, replacing with fresh medium containing the sample once every 2-3 days. After the cells finished growing, they were collected and compared with the color of the cells of the control group, Example 1, and Comparative Examples 1 to 3, respectively. Further, after removing the culture medium and washing with PBS, after dissolving in 1N sodium hydroxide and measuring the absorbance at 500 nm, the melanin production inhibition rate was calculated by the following mathematical formula 1, and the results are shown in Table 1 below. It was shown to.
前記表1の結果から、ミカンの皮抽出物と緑茶抽出物を共に使用した実施例1を使用すると、美白効果が非常に優れたものと知られているコウジ酸と類似するメラニン生成抑制率を有することが分かった。また、ミカンの皮抽出物と緑茶抽出物をそれぞれ使用した比較例2及び比較例3に比べて、4〜5倍に達する非常に優れたメラニン生成抑制率を示した。これは、ミカンの皮抽出物に含まれたタンゲレチンと緑茶抽出物に含まれたEGCGのシナジー効果により、メラニン生成抑制効果が上昇したものである。 From the results of Table 1, when Example 1 using both mandarin orange extract and green tea extract is used, the inhibition rate of melanin production similar to kojic acid, which is known to have a very good whitening effect, is obtained. It turns out to have. Moreover, compared with the comparative example 2 and the comparative example 3 which respectively used the mandarin orange peel extract and the green tea extract, the very outstanding melanin production suppression rate which reached 4 to 5 times was shown. This is because the melanin production inhibitory effect is increased by the synergistic effect of tangeretin contained in the citrus peel extract and EGCG contained in the green tea extract.
[製造例1及び比較製造例1〜4]
下記の表2に記載された組成により、製造例1及び比較製造例1〜4の化粧料組成物を製造した。その製造過程を詳細に調べると、原料1〜9を混合して70℃で溶解し、水相パートとし、一方、原料10〜15を70℃で溶解してオイルパートとする。オイルパートを前記水相パートに添加してホモミキサー(日本Tokushu Kika社)で撹拌して1次乳化し、原料16及び17を添加して増粘した。気泡を除去した後、室温で冷却して製造例1及び比較製造例1〜4の化粧料を製造した(単位:質量%)。
Cosmetic compositions of Production Example 1 and Comparative Production Examples 1 to 4 were produced with the compositions described in Table 2 below. When the manufacturing process is examined in detail, the raw materials 1 to 9 are mixed and dissolved at 70 ° C. to form an aqueous phase part, while the raw materials 10 to 15 are dissolved at 70 ° C. to form an oil part. The oil part was added to the aqueous phase part and stirred with a homomixer (Nippon Tokushu Kika) to perform primary emulsification, and then the raw materials 16 and 17 were added to increase the viscosity. After removing the bubbles, the mixture was cooled at room temperature to produce cosmetics of Production Example 1 and Comparative Production Examples 1 to 4 (unit: mass%).
[試験例2]人体皮膚に対する美白効果
人体皮膚に対する美白効果と皮膚刺激性を調べるために、平均年齢35.2歳の元気な30人の男性及び女性を対象にして、被検者の上腕部位に直径1.5cmの穴6個があけられた不透明テープを付着した後、各被検者の最小紅斑量(Minimal Erythema Dose)の1.5〜2倍程度の紫外線(UVB)を照射して皮膚の黒化を誘導し、試験物質を塗布して、二ヶ月後、色差計を利用して皮膚の明暗を測定した。これら被検者に前記製造例1及び比較製造例1〜4の化粧料を朝、夕方2回ずつ毎日塗るようにした。
[Test Example 2] Whitening effect on human skin In order to examine the whitening effect and skin irritation on human skin, the upper arm region of a subject was examined for 30 healthy men and women with an average age of 35.2 years old. After adhering an opaque tape with 6 holes of 1.5 cm in diameter, the sample was irradiated with ultraviolet rays (UVB) of about 1.5 to 2 times the minimum erythema dose of each subject. Skin darkening was induced, the test substance was applied, and two months later, the lightness of the skin was measured using a color difference meter. These subjects were allowed to apply the cosmetics of Production Example 1 and Comparative Production Examples 1 to 4 twice daily in the morning and evening.
効果の判定は、皮膚の明暗を示す「L」の値を求めて決めた。参考として、人為的に焼いていない韓国人の肌色は、一般的に50〜70の値を示す。色差計(ミノルタCR2002)を用いて皮膚の白黒程度を測定し、効果を判定した。色を表示するにはL*a*b*表色系を使用するが、本発明では主にL*値(明度)を指標とした。L*値は標準白板で校正して、測定は1つの部位に5回以上の測定を繰り返すことにより、色素沈着部を均等に測定した。塗布開始時点と完了時点における肌色の差(△L*)を下記の数学式2により計算し、これを下記の表3に示した。美白効果は、試料塗布部位と対照群部位の△L*の比較から判定するが、△L*値が2程度であれば、沈着された色素の美白化が明確であると判定し、1.5程度以上であれば、美白効果があると判定することができる。 The effect was determined by determining the value of “L” indicating the brightness of the skin. As a reference, the skin color of Koreans not artificially baked generally shows a value of 50-70. Using a color difference meter (Minolta CR2002), the black and white level of the skin was measured to determine the effect. In order to display the color, the L * a * b * color system is used. In the present invention, L * value (lightness) is mainly used as an index. The L * value was calibrated with a standard white plate, and the measurement was repeated five times or more at one site, thereby uniformly measuring the pigmented portion. The difference in skin color (ΔL *) between the application start time and the completion time was calculated by the following mathematical formula 2, which is shown in Table 3 below. The whitening effect is determined by comparing ΔL * of the sample application site and the control group site. If the ΔL * value is about 2, it is determined that the whitening of the deposited pigment is clear. If it is about 5 or more, it can be determined that there is a whitening effect.
試験物質を塗布して効果のある場合には、L値が順次増加することになり、試験物質の比較は、塗布開始時点と完了時点(塗布開始二ヶ月後)における肌色の差(△L)を前記数学式2により計算し、その結果を下記の表3に示した。 When the test substance is applied and effective, the L value will increase sequentially, and the test substance is compared with the difference in skin color (ΔL) between the start of application and the end of application (two months after the start of application). Was calculated by the mathematical formula 2 and the results are shown in Table 3 below.
[試験例3]人体皮膚に対する皮膚刺激感の調査
前記試験例2の被検者を対象にして、製造例1及び比較製造例1〜4の化粧料を二ヶ月間使用するようにした後、皮膚刺激感を比較した。このとき、判断基準は、被検者が刺激感の程度により点数を1〜5まで付与して比較したもので、1に近いほど刺激がなく、5に近いほど刺激が多いことを意味し、それぞれの平均点数を下記の表3に示した。
[Test Example 3] Investigation of skin irritation to human skin After using the cosmetics of Production Example 1 and Comparative Production Examples 1 to 4 for the subject of Test Example 2 for two months, The skin irritation was compared. At this time, the judgment standard is that the subject gave a score of 1 to 5 according to the degree of irritation and compared, meaning that there is no stimulation as it is closer to 1, and there is more stimulation as it is closer to 5, The average score for each is shown in Table 3 below.
前記表3の結果から分かるように、本発明によるミカンの皮抽出物と緑茶抽出物を混合して使用した製造例1の化粧料の方が、比較製造例1よりも美白効果が優れており、同時に皮膚刺激がコウジ酸を同量で使用する時と類似値を有することを確認することができた。また、ミカンの皮抽出物と緑茶抽出物を混合して使用した製造例1の方が、比較製造例3及び4の化粧料よりも、やはり約4〜5倍以上の顕著に優れた美白効果を有するだけでなく、皮膚刺激感も非常に減少したことが分かった。これは、ミカンの皮抽出物に含まれたタンゲレチンと緑茶抽出物に含まれたEGCGとの混合による相乗効果によるものであると判断される。 As can be seen from the results in Table 3, the cosmetic of Production Example 1 using a mixture of citrus peel extract and green tea extract according to the present invention has a whitening effect better than Comparative Production Example 1. At the same time, it was confirmed that the skin irritation had a similar value as when kojic acid was used in the same amount. Moreover, the whitening effect of the manufacture example 1 which mixed and used the orange extract of the mandarin orange and the green tea extract is also the outstanding whitening effect of about 4 to 5 times more than the cosmetics of the comparative manufacture examples 3 and 4. It was found that the skin irritation feeling was also greatly reduced. This is determined to be due to a synergistic effect of mixing tangeretin contained in the citrus peel extract and EGCG contained in the green tea extract.
[試験例4]角質量の変化
本発明による美白化粧料組成物の角質量減少効果を調べるために、製造例1及び比較製造例1〜4から製造した化粧料の皮膚角質量の変化を調べてみた。
皮膚疾患のない20〜30代の成人男女50人の下膊内側に製造例1及び比較製造例1〜4の化粧料組成物を塗布した後、24時間が経過して、チャームビュー(Charm view;Moritex,Japan)を利用して角質減少量を測定した。あらかじめ塗布開始前、恒温、恒湿条件(24℃、湿度40%)でチャームビューを利用して初期皮膚角質量を測定して基本値とし、24時間経過後の変化を測定した。その結果を下記の表4に示した。
[Test Example 4] Change in angular mass In order to examine the effect of reducing the angular mass of the whitening cosmetic composition according to the present invention, the change in skin angular mass of the cosmetics produced from Production Example 1 and Comparative Production Examples 1 to 4 was examined. I tried.
After applying the cosmetic compositions of Production Example 1 and Comparative Production Examples 1 to 50 on the lower arm of 50 adult men and women in their 20s and 30s who have no skin disease, 24 hours have passed and Charm view (Charm view) The amount of keratin loss was measured using Moritex, Japan). Prior to the start of application, the initial skin angular mass was measured using a charm view under constant temperature and humidity conditions (24 ° C., humidity 40%) to obtain a basic value, and the change after 24 hours was measured. The results are shown in Table 4 below.
前記表4の結果から、本発明による美白化粧料組成物の製造例1が比較製造例1〜4に比べて皮膚角質減少効果が優れていることが分かる。また、ミカンの皮抽出物と緑茶抽出物とを混合して製造した製造例1の場合、シナジー効果によって最も優れた皮膚角質減少効果を有することが分かる。 From the results of Table 4, it can be seen that Production Example 1 of the whitening cosmetic composition according to the present invention is superior in skin keratin reduction effect as compared with Comparative Production Examples 1 to 4. Moreover, in the case of the manufacture example 1 manufactured by mixing the tangerine peel extract and the green tea extract, it can be seen that the synergistic effect has the most excellent skin keratin reduction effect.
したがって、本発明によるタンゲレチンにEGCGをさらに含有する組成物は、皮膚に安全ながら優れた美白効果とともに、皮膚刺激を最小化して優れた皮膚安全性を提供できることを確認することができた。 Therefore, it was confirmed that the composition further comprising EGCG in tangeretin according to the present invention can provide excellent skin safety by minimizing skin irritation, as well as excellent skin whitening effect.
[試験例5]フリー・ラジカル除去能評価:DPPH assay
DPPH(2,2−Diphenyl−1−picrylhydrazyl,Sigma,D9132)を利用してタンゲレチンとEGCGの混合使用によるフリー・ラジカル消去能を確認するために、DPPH assayを実施した。紫色を帯びているDPPHは、抗酸化物質と反応をすると、抗酸化物質から水素電子を受けることになり、色が変化し、517nmでの吸光度が減少する。
[Test Example 5] Evaluation of free radical removal ability: DPPH assay
In order to confirm the free radical scavenging ability by the mixed use of tangeretin and EGCG using DPPH (2,2-Diphenyl-1-picrylhydrazyl, Sigma, D9132), DPPH assay was performed. When DPPH, which has a purple color, reacts with an antioxidant substance, it receives hydrogen electrons from the antioxidant substance, changes its color, and the absorbance at 517 nm decreases.
まず、DPPHを準備し、実験を始める前にエタノールに溶かして100μMに作って、超音波分解(sonication)を実施して完全に溶かした後、次の順序で処理物質を準備する。
1)タンゲレチン10%溶液〔溶媒:ジメチルスルホキシド(DMSO)〕を処理濃度によりエタノールに希釈する。
2)物質の処理濃度区間ごとに、同じ濃度の処理回数を3回とする。
3)DPPH溶液と反応させる時は、濃度が1/20に低まるので、確認しようとする濃度の20倍の物質を準備する。
First, DPPH is prepared. Before starting the experiment, it is dissolved in ethanol to make 100 μM, sonication is performed and completely dissolved, and then the treatment substances are prepared in the following order.
1) Dilute a 10% tangeretin solution [solvent: dimethyl sulfoxide (DMSO)] in ethanol according to the treatment concentration.
2) The number of treatments with the same concentration is set to 3 for each treatment concentration interval of the substance.
3) When reacting with DPPH solution, the concentration is reduced to 1/20, so prepare a substance 20 times the concentration to be confirmed.
その後、前記処理物質を処理濃度別に10μLずつ96−ウェルプレートに入れる。陽性対照群にはビタミンCを2.5、5、10ppm濃度で各々10μLずつ入れる。対照群にはエタノールを10μL入れる。その後、100μMのDPPHを190μLずつ入れて、物質に色がある場合には吸光度に影響を及ぼし得るので、物質10μLにエタノールを190μL入れる実験群も作っておく。 Thereafter, 10 μL of the treatment substance is placed in a 96-well plate for each treatment concentration. In the positive control group, 10 μL of vitamin C is added at 2.5, 5, and 10 ppm concentrations. The control group contains 10 μL of ethanol. Thereafter, 190 μL of 100 μM DPPH is added, and if the substance has color, the absorbance can be affected. Therefore, an experimental group in which 190 μL of ethanol is added to 10 μL of substance is also prepared.
物質反応は、37℃のインキュベーターで30分間保管した後、分光光度計(Spectra Max 190)を利用して、517nmにおける吸光度を測定する。ビタミンC、EGCGを含有する緑茶抽出物、タンゲレチンを含有するミカンの皮抽出物、及びタンゲレチンを含有するミカンの皮抽出物にEGCGを含有する緑茶抽出物を混合して使用した場合を、濃度変化によって吸光度値(O.D.)を測定し、図1に示した。 The substance reaction is stored for 30 minutes in an incubator at 37 ° C., and then the absorbance at 517 nm is measured using a spectrophotometer (Spectra Max 190). Concentration change when green tea extract containing EGCG is mixed with green tea extract containing vitamin C and EGCG, mandarin peel extract containing tangeretin, and mandarin peel extract containing tangeretin The absorbance value (OD) was measured by the method shown in FIG.
物質の抗酸化力が大きいほど吸光度値は低い。対照群と比較して吸光度値を半分に落とす物質の濃度(IC50:50% Inhibitory activity)を求めた。IC50値が小さいほど抗酸化力が大きいと判断することができる。 The greater the antioxidant power of the substance, the lower the absorbance value. The concentration (IC50: 50% Inhibitory activity) of the substance that reduces the absorbance value in half compared with the control group was determined. It can be determined that the smaller the IC50 value, the greater the antioxidant power.
図1中に記載の「*」は、タンゲレチンを含有するミカンの皮抽出物(−)と、タンゲレチンを含有するミカンの皮抽出物にEGCGを含有する緑茶抽出物を混合して使用した場合(+)との間に「有意差」があることを示すものであり、実験結果から算出されたp−valueが0.05未満であるため、信頼できる有意性を有しているものと認められる。この図1の結果によれば、すべての濃度で、EGCGとタンゲレチンをそれぞれ単独で処理する時に比べて、この二つを共に処理する時、有意的な差として抗酸化効果があることを確認することができた。 In FIG. 1, “*” indicates a case where a mandarin peel extract (−) containing tangeretin and a green tea extract containing EGCG are mixed with a mandarin peel extract containing tangeretin ( +) Indicates that there is a “significant difference” and the p-value calculated from the experimental results is less than 0.05, which is considered to have reliable significance. . According to the results of FIG. 1, it is confirmed that there is an antioxidant effect as a significant difference when treating both EGCG and tangeretin at all concentrations as compared to when treating both alone. I was able to.
また、図1中の写真は、この試験例5のDPPH assayにおける色の変化を表したものである。紫色を帯びたDPPHは、抗酸化物質と反応すると、抗酸化物質から水素電子を受けて、色が変化する。EGCGとタンゲレチンをそれぞれ単独で処理した時に比べて、この二つを共に処理した時には、対照群の濃い紫色が有意に薄くなることが分かった。
したがって、タンゲレチンとEGCGの抗酸化シナジー効果を通じて美白効果だけでなく、皮膚の酸化を防ぎ、皮膚に活気を与えることを確認することができた。
Moreover, the photograph in FIG. 1 represents the color change in DPPH assay of Test Example 5. When the purple DPPH reacts with an antioxidant substance, it receives hydrogen electrons from the antioxidant substance and changes its color. It was found that when the two were treated together, the dark purple color of the control group was significantly lighter than when EGCG and tangeretin were treated alone.
Therefore, it was confirmed that not only the whitening effect through the antioxidant synergy effect of tangeretin and EGCG but also the prevention of skin oxidation and vitality of the skin.
下記、本発明に係る化粧料組成物及び薬学組成物の剤形例を説明するが、下記の例示の以外にも様々な剤形に応用が可能であり、これは、本発明を限定しようとするものではなく、単に具体的に説明するためである。 Examples of dosage forms of the cosmetic composition and pharmaceutical composition according to the present invention will be described below. However, the present invention can be applied to various dosage forms other than those exemplified below, and this is intended to limit the present invention. It is not intended to be described, but merely for concrete explanation.
[剤形例1]柔軟化粧水(スキンローション)
下記表5に記載された組成により、通常の方法で柔軟化粧水を製造した。
[Form example 1] Soft lotion (skin lotion)
According to the composition described in Table 5 below, a soft lotion was produced by an ordinary method.
[剤形例2]栄養化粧水(ミルクローション)
下記の表6に記載された組成により、通常の方法で栄養化粧水を製造した。
[Form example 2] Nutrition lotion (milk lotion)
With the composition described in Table 6 below, a nutritive lotion was produced by a conventional method.
[剤形例3]栄養クリーム
下記の表7に記載された組成により、通常の方法で栄養クリームを製造した。
[Dosage Form Example 3] Nutrition Cream Nutrition cream was produced by the usual method according to the composition described in Table 7 below.
[剤形例4]マッサージクリーム
下記の表8に記載された組成により、通常の方法でマッサージクリームを製造した。
[Formulation Example 4] Massage Cream A massage cream was produced by the usual method according to the composition described in Table 8 below.
[剤形例5]パック
下記の表9に記載された組成により、通常の方法でパックを製造した。
[Dosage Form Example 5] Pack A pack was produced by the usual method according to the composition described in Table 9 below.
[剤形例6]局所投与用薬剤(パッチ剤)
下記の表10に記載された組成により、通常の方法でパッチ剤を製造した。
[Formulation Example 6] Drug for local administration (patch)
A patch was prepared by the usual method according to the composition described in Table 10 below.
本発明が属した分野で通常の知識を有する者であれば、前記の内容に基づいて本発明の範疇内で多様な応用及び変形を行うことが可能である。 A person having ordinary knowledge in the field to which the present invention belongs can make various applications and modifications within the scope of the present invention based on the above contents.
以上、本発明の特定の部分を詳細に記述したところ、当業界の通常の知識を有する者にとって、具体的な技術は単に好ましい実現例に過ぎず、これにより、本発明の範囲が制限されないのは明らかである。したがって、本発明の実質的な範囲は、添付する請求項とその等価物によって定義される。 In the above, specific portions of the present invention have been described in detail. For those having ordinary skill in the art, the specific technique is merely a preferred implementation example, and the scope of the present invention is not limited thereby. Is clear. Accordingly, the substantial scope of the present invention is defined by the appended claims and equivalents thereof.
Claims (3)
前記ミカンの皮抽出物は、乾燥されたミカンの皮を室温で冷浸抽出して1次濾過した後、遠心分離して上層液を取り、これを再び2次濾過し、さらに、1,3−ブチレングリコール、フェノキシエタノール及びエチルヘキシルグリセリンの混合液を加えて抽出した後、3次濾過して得たものであり、
前記緑茶抽出物は、乾燥された茶葉を室温で冷浸抽出して1次濾過した後、遠心分離して上層液を取り、これを再び2次濾過し、さらに、1,3−ブチレングリコール、フェノキシエタノール及びエチルヘキシルグリセリンの混合液を加えて抽出した後、3次濾過して得たものであることを特徴とする角質除去用皮膚外用剤組成物。 Contains both citrus peel extract and green tea extract as active ingredients ,
The citrus peel extract was subjected to primary filtration after chilled extraction of dried citrus peel at room temperature, and then centrifuged to obtain an upper layer liquid, which was subjected to secondary filtration again, and further to 1, 3 -It was obtained by adding a mixed liquid of butylene glycol, phenoxyethanol and ethylhexylglycerin and then performing third filtration,
The green tea extract is obtained by subjecting dried tea leaves to cold extraction at room temperature and performing primary filtration, and then centrifuging to obtain an upper layer liquid, which is subjected to secondary filtration again, and further, 1,3-butylene glycol, A skin external preparation composition for removing keratin, which is obtained by adding and extracting a mixed solution of phenoxyethanol and ethylhexylglycerin, followed by tertiary filtration .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0009469 | 2012-01-31 | ||
KR1020120009469A KR20130088912A (en) | 2012-01-31 | 2012-01-31 | Skin external composition containing tangeretin and egcg |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013155174A JP2013155174A (en) | 2013-08-15 |
JP6387219B2 true JP6387219B2 (en) | 2018-09-05 |
Family
ID=48833731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013015044A Active JP6387219B2 (en) | 2012-01-31 | 2013-01-30 | Skin external preparation composition containing tangeretin and EGCG |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP6387219B2 (en) |
KR (1) | KR20130088912A (en) |
CN (1) | CN103222930B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190290574A1 (en) * | 2015-12-08 | 2019-09-26 | University Of Pretoria | Topical skin care compositions comprising myrsine africana extracts |
CN108391816A (en) * | 2017-02-08 | 2018-08-14 | 阙燕娣 | A kind of production method of antioxidant healthcare capsule |
KR102610940B1 (en) * | 2017-02-24 | 2023-12-08 | (주)아모레퍼시픽 | Preparing method of cosmetic composition using skin cosmetic solution |
TWI754037B (en) | 2017-04-03 | 2022-02-01 | 大江生醫股份有限公司 | Composition containing plant extracts and uses thereof for reducing fat |
CN107028827A (en) * | 2017-04-17 | 2017-08-11 | 广州市聚吉科绿色化学共性技术研究院有限公司 | A kind of natural anti-oxidation lipstick |
CN108653478A (en) * | 2017-09-06 | 2018-10-16 | 四川云想科技有限公司 | A kind of antibacterial anti-inflammatory externally-used embrocation and its preparation method and application |
CN112006959B (en) * | 2020-09-15 | 2022-08-23 | 上海应用技术大学 | Antioxidant whitening cream containing dandelion and tea extracts and preparation method thereof |
WO2023212371A2 (en) * | 2022-04-28 | 2023-11-02 | L'oreal | Compositions suitable as setters |
FR3137566A1 (en) * | 2022-07-05 | 2024-01-12 | L'oreal | COMPOSITIONS SUITABLE AS FIXATORS |
CN114990169B (en) * | 2022-06-16 | 2023-07-28 | 中国农业科学院茶叶研究所 | Method for preparing EGCG-3' -Me |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3911991B2 (en) * | 2000-09-28 | 2007-05-09 | 株式会社ナリス化粧品 | Active oxygen scavenger and cosmetics |
US20070003536A1 (en) * | 2000-11-21 | 2007-01-04 | Zimmerman Amy C | Topical skin compositions, their preparation, and their use |
JP3766018B2 (en) * | 2001-12-17 | 2006-04-12 | 一丸ファルコス株式会社 | Active oxygen scavenger |
JP2006117613A (en) * | 2004-10-25 | 2006-05-11 | Ichimaru Pharcos Co Ltd | Melanogenesis inhibitor |
KR102142311B1 (en) * | 2011-12-16 | 2020-08-10 | (주)아모레퍼시픽 | Skin external composition comprising tangeretin |
-
2012
- 2012-01-31 KR KR1020120009469A patent/KR20130088912A/en active Search and Examination
-
2013
- 2013-01-07 CN CN201310004543.6A patent/CN103222930B/en active Active
- 2013-01-30 JP JP2013015044A patent/JP6387219B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2013155174A (en) | 2013-08-15 |
CN103222930A (en) | 2013-07-31 |
CN103222930B (en) | 2017-08-29 |
KR20130088912A (en) | 2013-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6387219B2 (en) | Skin external preparation composition containing tangeretin and EGCG | |
KR101695002B1 (en) | Composition of skin external application containing propanoid derivatives | |
JP5628797B2 (en) | Skin external preparation composition containing ginseng flower or ginseng seed extract | |
KR20200026646A (en) | Cosmetic Composition for Improving Skin Condition Comprising Plant cell complex cultures to improve skin radiance and vitality | |
KR101387308B1 (en) | Skin whitening composition by using of dendropanax morbifera ferment extract | |
BR112021001150A2 (en) | botanical and bacterial extracts that exhibit retinol-like activity | |
CN107412031B (en) | Skin external composition containing hesperetin | |
JP6921440B2 (en) | Composition for promoting melanin production containing thistle extract as an active ingredient | |
KR20120003178A (en) | Composition with skin lightening and moisturizing effects containing bee venom extracts | |
KR101885199B1 (en) | Cosmetic composition containing the mixed extract of pomegranate, rosa centifolia flower, carthamus tinctorius and rosa rugosa | |
BR102014018002A2 (en) | compositions comprising mallow neglect extract | |
JP2015155394A (en) | photoaging inhibitor | |
KR102226179B1 (en) | Cosmetic Compositions for Anti-aging Comprising Extracts of Plants | |
KR101969684B1 (en) | A cosmetic composition for anti-wrinkle and skin pore reduction containing natural spicule powder and natural complex extract | |
KR102056620B1 (en) | External composition for skin containing Cannabis sativa extract | |
JP2005247826A (en) | Decorin production-promoting agent and skin care preparation for external use containing the same | |
KR102455132B1 (en) | Cosmetic composition containing lemon myrtle extract and its manufacturing method | |
KR20090097550A (en) | Cosmetic composition containing schizandrin and extracts | |
KR20130115482A (en) | Skin external composition comprising germinated camellia sinensis seed extract | |
JP2008247787A (en) | External preparation for skin | |
JP5155543B2 (en) | Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method | |
KR20160000318A (en) | Cosmetic composition containing Fir tree oil | |
KR102468538B1 (en) | Skin improvement composition containing wild geranium extract with excellent antioxidant, whitening and anti-inflammatory effects | |
KR101844980B1 (en) | External composition for skin containing extract of Salix blinii H.Lev. | |
JP2004137166A (en) | Skin care preparation for external use, cell activator and antioxidant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160127 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170711 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171011 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20180117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180703 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180724 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180813 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6387219 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |